Literature DB >> 20061699

The long-term results of pediatric patients with primary focal and segmental glomerulosclerosis.

Betul Sozeri1, Sevgi Mir, Fatma Mutlubas, Sait Sen.   

Abstract

Focal and segmental glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and end-stage renal disease (ESRD). In this retrospective study, we report on 34 pediatric patients with FSGS who were diagnosed and treated from 1992 to 2006. The mean age at onset was 6.3 + or - 4.3 years. All patients had nephrotic-range proteinuria. Microscopic hematuria was seen in three patients and hypertension was seen in 15 patients at presentation. All patients were treated with steroids (oral and/or methylprednisolone), while 23 patients received cytotoxic therapy in addition. The mean follow-up period was 8.6 + or - 3.3 years at the end of which, 59% of patients achieved complete or partial remission, 20.5% continued to have active renal disease while 20.5% of the patients developed CKD. Our study suggests that most of the patients with FSGS progress to renal insufficiency. Steroid therapy increases the chances of remission and preserves renal function in patients with sporadic primary FSGS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061699

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  4 in total

1.  Rituximab for refractory cases of childhood nephrotic syndrome.

Authors:  Jameela A Kari; Salah M El-Morshedy; Sherif El-Desoky; Hammad O Alshaya; Khawla A Rahim; Burhan M Edrees
Journal:  Pediatr Nephrol       Date:  2011-01-31       Impact factor: 3.714

Review 2.  Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.

Authors:  Jeremy Kiffel; Yael Rahimzada; Howard Trachtman
Journal:  Adv Chronic Kidney Dis       Date:  2011-09       Impact factor: 3.620

3.  Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran.

Authors:  Fakhrossadat Mortazavi; Yaser Soleimani Khiavi
Journal:  Ther Clin Risk Manag       Date:  2011-05-27       Impact factor: 2.423

4.  Citral is renoprotective for focal segmental glomerulosclerosis by inhibiting oxidative stress and apoptosis and activating Nrf2 pathway in mice.

Authors:  Shun-Min Yang; Kuo-Feng Hua; Yu-Chuan Lin; Ann Chen; Jia-Ming Chang; Louis Kuoping Chao; Chen-Lung Ho; Shuk-Man Ka
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.